Try our beta test site
Trial record 2 of 10 for:    Solana

A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation (SOLANA)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2017 by AstraZeneca
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT02869438
First received: August 16, 2016
Last updated: February 28, 2017
Last verified: February 2017
  Purpose
The purpose of this study is to investigate the onset and maintenance of effect of benralizumab on lung function, blood eosinophils, asthma control metrics and quality of life during 12-week treatment in patients with uncontrolled, severe asthma with eosinophilic inflammation. A subset of patients will take part in body plethysmography substudy to further investigate the effect on lung function.

Condition Intervention Phase
Asthma
Drug: Benralizumab
Other: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Other
Official Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Effect of benralizumab on the time course of change on lung function [ Time Frame: Day 84 (Visit 10) ]
    Change from baseline to end of treatment between benralizumab and placebo in pre-BD FEV1

  • Effect of benralizumab on the time course of change in lung function as assessed through body plethysmography [ Time Frame: Day 84 (Visit 10) ]

    Change from baseline to end of treatment in the following measures compared to placebo:

    Residual volume (RV)



Secondary Outcome Measures:
  • Effect of benralizumab on the time course of change and maintenance on lung function [ Time Frame: Day 84 (Visit 10) ]
    Change from baseline in pre-BD FEV1 and pre-BD FVC at all clinic visits compared to placebo

  • Time course of effect of benralizumab on blood eosinophils and correlate changes in eosinophil depletion with lung function [ Time Frame: Day 84 (Visit 10) ]
    Change from baseline in blood eosinophils (from hematology) to end of treatment together with the correlation with lung function

  • Time course of the effect of benralizumab on asthma control metrics [ Time Frame: Day 84 (Visit 10) ]
    Change from baseline in Asthma Control Quesitonnaire-6 (ACQ-6) score at all post-baseline timepoints

  • Time course of effect of benralizumab on health related quality of life [ Time Frame: Day 84 (Visit 10) ]
    Change from baseline in St. George's Respiratory Questionnaire (SGRQ) score at all postbaseline assessment timepoints

  • Effect of benralizumab on the time course of change in exhaled nitric oxide (FeNO) [ Time Frame: Day 84 (Visit 10) ]
    Change from baseline in FeNO (ppb) compared to placebo to end of treatment

  • Effect of benralizumab on the time course of change in lung function as assessed through body plethysmography [ Time Frame: Day 84 (Visit 10) ]

    Change from baseline (Visit 4) to end of treatment (Visit 10) in the following measures compared to placebo :

    • Total lung capacity (TLC)
    • RV/TLC ratio
    • Inspiratory capacity (IC)
    • Functional residual capacity (FRC)
    • Vital capacity (VC)


Other Outcome Measures:
  • Evaluation of the pharmacokinetics (PK) and immunogenicity of benralizumab [ Time Frame: Day 84 (Visit 10) ]
    • Serum PK
    • Anti-drug antibodies

  • Assessment the safety and tolerability of benralizumab [ Time Frame: Day 84 (Visit 10) ]
    • Adverse events (AEs) and serious adverse events (SAEs)
    • Laboratory variables
    • Physical Examination

  • Evaluation of patient impression of overall asthma severity (PGI-S) and overall change from baseline as reported by the patient (PGIC) and clinician (CGI-C) [ Time Frame: Day 84 (Visit 10) ]
    • Change from baseline in PGI-S at all post-baseline assessment timepoints
    • Clinician-reported global change in asthma from baseline as measured by CGI-C
    • Patient-reported global change in asthma from baseline as measured by PGI-C

  • Effect of benralizumab on the time course of change in lung function as assessed through body plethysmography [ Time Frame: Day 84 (Visit 10) ]

    Change from baseline to end of treatment in the following measures compared to placebo:

    • Specific airway resistance (SGaw)
    • Airway resistance (Raw)


Estimated Enrollment: 230
Study Start Date: November 2016
Estimated Study Completion Date: May 2018
Estimated Primary Completion Date: May 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Benralizumab arm
Benralizumab administered subcutaneously
Drug: Benralizumab
Benralizumab administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
Placebo Comparator: Placebo arm
Placebo administered subcutaneously
Other: Placebo
Placebo administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria

  1. Written informed consent for study participation must be obtained prior to any study related procedures being performed and according to international guidelines and/or applicable European Union (EU) guidelines.
  2. Female and male aged 18 to 75 years inclusively at the time of Visit 1
  3. Documented current treatment with ICS and LABA for at least 30 days prior to Visit 1. The ICS and LABA can be parts of a combination product or given by separate inhalers. The ICS dose must be greater than or equal to 500 μg/day fluticasone propionate dry powder formulation or equivalent daily. Additional asthma controller medications, eg, oral corticosteroids, long-acting antimuscarinics (LAMAs), LTRAs, theophylline etc. are allowed if they have been used for at least 30 days prior to Visit 1
  4. History of at least 2 asthma exacerbations that required treatment with systemic corticosteroids (intramuscular (IM), intravenous (IV), or oral) in the 12 months prior to Visit 1. For patients receiving corticosteroids as a maintenance therapy, the corticosteroid treatment for the exacerbation is defined as a temporary increase of their maintenance dose.
  5. Pre-bronchodilator (pre-BD) FEV1 of < 80% predicted at Visit 2 or Visit 3
  6. ACQ-6 score ≥1.5 at Visit 1
  7. Evidence of asthma as documented by airway reversibility (FEV1 ≥12% and 200 ml) demonstrated at Visit 1, Visit 2 or Visit 3. For patients entering the body plethysmography sub-study, reversibility must be demonstrated at Visit 1 or at Visit 2 only
  8. Peripheral blood eosinophil count of ≥300 cells/μL assessed by central lab at Visit 1
  9. Women of childbearing potential (WOCBP) must use an effective form of birth control confirmed by the Investigator. WOCBP must also have negative serum pregnancy test result on Visit 1.

    Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for 12 months prior to the planned date of randomization without an alternative medical cause. The following agespecific requirements apply:

    • Women <50 years old are considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone (FSH) levels in the postmenopausal range.
    • Women ≥50 years old are considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment.
  10. All male patients who are sexually active must agree to use a double barrier method of contraception (condom with spermicide) from the first dose of IP until 16 weeks after their last dose
  11. Weight of ≥40 kg

Additional inclusion criteria applicable for the Body Plethysmography substudy 1.Residual volume ≥125% of predicted at Visit 3.

Inclusion criteria at randomization visit

  1. At least 1 of the following within 7 days prior to randomization:

    • Daytime or nighttime asthma symptoms for 2 or more days;
    • Rescue SABA use for 2 or more days;
    • Nighttime awakenings due to asthma at least 1 night during the 7-day period
  2. ACQ >0.75 at Visit 4 prior to randomization.
  3. A negative urine pregnancy test in WOCBP prior to administration of IP

Exclusion criteria

  1. Clinically important pulmonary disease other than asthma (eg, active lung infection, COPD, bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (eg, allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome)
  2. Life-threatening asthma defined as episodes requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma related syncopal episodes within the 12 months prior to Visit 1.
  3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screening/run-in period
  4. An upper respiratory tract infection or an asthma exacerbation that required treatment with systemic corticosteroids or an increase in regular maintenance dose of OCS during the screening/run-in period prior to randomization Visit 4
  5. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:

    • Affect the safety of the patient throughout the study
    • Influence the findings of the studies or their interpretations
    • Impede the patient's ability to complete the entire duration of study
  6. Known history of allergy or reaction to any component of the investigational product formulation
  7. History of anaphylaxis to any biologic therapy
  8. History of Guillain-Barré syndrome
  9. A helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent is obtained that has not been treated with, or has failed to respond to standard of care therapy
  10. Any clinically significant abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during screening period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study
  11. Any clinically significant cardiac disease or any electrocardiogram (ECG) abnormality obtained during the screening/run-in period, which in the opinion of the Investigator may put the patient at risk or interfere with study assessments
  12. History of alcohol or drug abuse within 12 months prior to the date informed consent is obtained
  13. Positive hepatitis B surface antigen, or hepatitis C virus antibody serology, or a positive medical history for hepatitis B or C. Patients with a history of hepatitis B vaccination without history of hepatitis B are allowed to enroll
  14. A history of known immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test
  15. Current smokers or former smokers with a smoking history of ≥10 pack years. A former smoker is defined as a patient who quit smoking at least 6 months prior to Visit 1
  16. Current malignancy, or history of malignancy, except for:

    • Patients who have had basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible provided that the patient is in remission and curative therapy was completed at least 12 months prior to the date informed consent was obtained.
    • Patients who have had other malignancies are eligible provided that the patient is in remission and curative therapy was completed at least 5 years prior to the date informed consent was obtained.
  17. Use of immunosuppressive medication (including but not limited to: oral corticosteroids [for reasons other than asthma], methotrexate, troleandomycin, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroids or any experimental anti-inflammatory therapy) within 3 months prior to the date informed consent
  18. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥1.5 times the upper limit of normal (ULN) confirmed during screening period
  19. Receipt of immunoglobulin or blood products within 30 days prior to the date informed consent is obtained
  20. Receipt of any marketed (eg, omalizumab, mepolizumab etc.) or investigational biologic within 4 months or 5 half-lives prior to the date informed consent is obtained, whichever is longer
  21. Receipt of live attenuated vaccines 30 days prior to the date of randomization
  22. Receipt of any investigational medication within 30 days or 5 half-lives prior to randomization, whichever is longer
  23. Previously received benralizumab (MEDI-563)
  24. Planned surgical procedures during the conduct of the study
  25. Currently breastfeeding or lactating women
  26. Previous randomization in the present study
  27. Concurrent enrolment in another interventional or post-authorization safety study (PASS).
  28. AstraZeneca staff involved in the planning and/or conduct of the study
  29. Employees of the study center or any other individuals involved with the conduct of the study or immediate family members of such individuals

Exclusion criteria at randomization Visit 4

1. Greater than/equal to 20% change in mean Pre BD FEV1 value at randomization Visit 4 from the mean pre BD FEV1 calculated from the pre BD FEV1 recorded at Visit 2 and Visit 3

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02869438

Contacts
Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com

  Show 36 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Rohit K. Katial, Professor of Medicine National Jewish Health, 1400 Jackson Street, M213, Denver, CO 80206, US
  More Information

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT02869438     History of Changes
Other Study ID Numbers: D3250C00038
2016-002094-36 ( EudraCT Number )
U1111-1185-6625 ( Other Identifier: WHO (UTN number) )
Study First Received: August 16, 2016
Last Updated: February 28, 2017

Keywords provided by AstraZeneca:
Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases

Additional relevant MeSH terms:
Asthma
Inflammation
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on March 23, 2017